Dividend Information About Abbott Laboratories: Everything You Need to Know Before Its Ex-Dividend Date on Oct 15, 2025

Abbott Laboratories (ABT) is set to pay a cash dividend of $0.59000 per share to shareholders of record on Oct 15, 2025, with the dividend expected to be distributed on Nov 17, 2025. The dividend was officially announced on Sep 19, 2025, and this payout of $0.59000 per share is notably higher than the average of the previous 10 dividend amounts, which stood at $0.28958 per share. The last dividend was also issued at the same amount of $0.59000 per share on Aug 15, 2025, and was also in the form of a cash dividend. Investors should be aware of the key dates in the dividend schedule: the announcement date was Sep 19, 2025, the ex-dividend date is Oct 15, 2025, and the payment date is Nov 17, 2025. This latest dividend reflects a continued commitment to returning value to shareholders, with a noticeable increase compared to historical averages.

Over the past week, Abbott Laboratories has remained a focal point in the financial news landscape, with several developments drawing investor attention. Notably, Benchmark recently initiated coverage of the stock with a Buy recommendation on Oct 10, 2025, signaling a positive outlook from analysts. Around the same time, Eastern Bank increased its holdings in ABT by 35.0% during the second quarter, highlighting growing institutional confidence in the company’s long-term prospects. Meanwhile, Coerente Capital Management slightly trimmed its stake in Abbott, reducing its position by 0.9% and currently holding 5.5% of its total holdings in the company. These movements suggest a mix of cautious optimism and strategic adjustments among key investors, reinforcing Abbott’s position as a company of interest in the healthcare sector.

As of late, Abbott has also been making strides in its biosimilars business, with recent developments indicating a broader push to bring advanced therapies to more patients. The company’s recent press releases have emphasized its commitment to expanding access to biologic medicines and biosimilars, which could play a pivotal role in its future revenue growth and market share expansion. These advancements align with Abbott’s broader strategic focus on innovation and diversification within the healthcare industry.

In conclusion, Abbott Laboratories continues to demonstrate a strong commitment to shareholder value through consistent and growing dividend payments, while also making progress in key areas of its core business. Investors should note that the ex-dividend date for the latest dividend is Oct 15, 2025, meaning that any purchase made after this date will not qualify for the dividend payment on Nov 17, 2025.